Neuro-fuzzy Models as an IVIVR Tool and Their Applicability in Generic Drug Development
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 2
Abstract
The online version of this article (doi:10.1208/s12248-014-9569-8) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Jerneja Opara, Igor Legen
Keywords
Related Articles
- EP ID EP681065
- DOI 10.1208/s12248-014-9569-8
- Views 291
- Downloads 0
Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs
The Biopharmaceutics Classification System (BCS) categorizes drugs into one of four biopharmaceutical classes according to their water solubility and membrane permeability characteristics and broadly allows the predictio...
Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases
With the advent of novel and personalized therapeutic approaches for cancer and inflammatory diseases, there is a growing demand for designing delivery systems that circumvent some of the limitation with the current ther...
Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans
Pharmacokinetic–pharmacodynamic (PK–PD) modeling greatly enables quantitative implementation of the “learn and confirm” paradigm across different stages of drug discovery and development....
Pharmacogenetic and Metabolic Differences Between Dog Breeds: Their Impact on Canine Medicine and the Use of the Dog as a Preclinical Animal Model
There is limited information describing species related pharmacogenetic differences in animals. Despite the lack of genetic information in veterinary medicine, breed specific responses to endogenous and exogenous substan...
Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development
The problem we have faced in drug development is in its efficiency. Almost a half of registration trials are reported to fail mainly because pharmaceutical companies employ one-size-fits-all development strategies. Our o...